Aromatase inhibitors in post-menopausal endometriosis

Reproductive Biology and Endocrinology

Volumn 9, Issue , 2011, Pages

  Polyzos, Nikolaos P ^a   Fatemi, Human M ^b   Zavos, Apostolos ^a   Grimbizis, Grigoris ^c   Kyrou, Dimitra ^c   Velasco, Juan Garcia ^d   Devroey, Paul ^b   Tarlatzis, Basil ^c   Papanikolaou, Evangelos G ^b,e  

^a UNIVERSITY HOSPITAL OF LARISSA   (Greece)

^b UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^d IVI Madrid   (Spain)

^e Human Reproduction and Genetics Foundation   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANASTROZOLE; AROMATASE INHIBITOR; CALCIUM; DANAZOL; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; EXEMESTANE; GESTAGEN; LETROZOLE; TAMOXIFEN; VITAMIN D; BISPHOSPHONIC ACID DERIVATIVE;

ABDOMINAL HYSTERECTOMY; AGE DISTRIBUTION; ARTHRALGIA; BONE DENSITY; BREAST CANCER; ENDOMETRIOSIS; ENZYME INHIBITION; ESTROGEN SYNTHESIS; FRACTURE; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; LONG TERM CARE; OSTEOPOROSIS; OVARIECTOMY; POSTMENOPAUSAL ENDOMETRIOSIS; RECURRENT DISEASE; REVIEW; RISK FACTOR; SIDE EFFECT; SMOKING; SYMPTOM; VAGINAL DRYNESS; AGED; BIOSYNTHESIS; FEMALE; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS;

AGED; AROMATASE INHIBITORS; DIPHOSPHONATES; ENDOMETRIOSIS; ESTROGENS; FEMALE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; POSTMENOPAUSE;

EID: 79959224585     PISSN: None     EISSN: 14777827     Source Type: Journal    
DOI: 10.1186/1477-7827-9-90     Document Type: Review

References (28)

1. Valle RF, Sciarra JJ. Endometriosis: treatment strategies. Ann N Y Acad Sci 2003, 997:229-239. 10.1196/annals.1290.026, 14644830.
2. Punnonen R, Klemi PJ, Nikkanen V. Postmenopausal endometriosis. Eur J Obstet Gynecol Reprod Biol 1980, 11:195-200. 10.1016/0028-2243(80)90069-6, 7194811.
3. Guy JM. Edgar Haydon (1859-1942): general practitioner and radium pioneer. J Med Biogr 2009, 17:127-134. 10.1258/jmb.2009.009015, 19723958.
4. Kempers RD, Dockerty MB, Hunt AB, Symmonds RE. Significant postmenopausal endometriosis. Surg Gynecol Obstet 1960, 111:348-356.
5. Goumenou AG, Chow C, Taylor A, Magos A. Endometriosis arising during estrogen and testosterone treatment 17 years after abdominal hysterectomy: a case report. Maturitas 2003, 46:239-241. 10.1016/S0378-5122(03)00081-1, 14585528.
6. Sesti F, Vettraino G, Pietropolli A, Marziali M, Piccione E. Vesical and vaginal recurrent endometriosis in postmenopause following estrogen replacement therapy. Eur J Obstet Gynecol Reprod Biol 2005, 118:265-266. 10.1016/j.ejogrb.2004.04.028, 15653219.
7. Fatemi HM, Al-Turki HA, Papanikolaou EG, Kosmas L, De Sutter P, Devroey P. Successful treatment of an aggressive recurrent post-menopausal endometriosis with an aromatase inhibitor. Reprod Biomed Online 2005, 11:455-457. 10.1016/S1472-6483(10)61140-6, 16274608.
8. Ackerman GE, Smith ME, Mendelson CR, MacDonald PC, Simpson ER. Aromatization of androstenedione by human adipose tissue stromal cells in monolayer culture. J Clin Endocrinol Metab 1981, 53:412-417. 10.1210/jcem-53-2-412, 7251819.
9. Brinton LA, Gridley G, Persson I, Baron J, Bergqvist A. Cancer risk after a hospital discharge diagnosis of endometriosis. Am J Obstet Gynecol 1997, 176:572-579. 10.1016/S0002-9378(97)70550-7, 9077609.
10. Borgfeldt C, Andolf E. Cancer risk after hospital discharge diagnosis of benign ovarian cysts and endometriosis. Acta Obstet Gynecol Scand 2004, 83:395-400.
11. Takayama K, Zeitoun K, Gunby RT, Sasano H, Carr BR, Bulun SE. Treatment of severe postmenopausal endometriosis with an aromatase inhibitor. Fertil Steril 1998, 69:709-713. 10.1016/S0015-0282(98)00022-3, 9548162.
12. Berlanda N, Vercellini P, Fedele L. The outcomes of repeat surgery for recurrent symptomatic endometriosis. Curr Opin Obstet Gynecol 2010, 22:320-325.
13. Mauri D, Pavlidis N, Polyzos NP, Ioannidis JP. Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. J Natl Cancer Inst 2006, 98:1285-1291. 10.1093/jnci/djj357, 16985247.
14. Meresman GF, Bilotas M, Abello V, Buquet R, Tesone M, Sueldo C. Effects of aromatase inhibitors on proliferation and apoptosis in eutopic endometrial cell cultures from patients with endometriosis. Fertil Steril 2005, 84:459-463. 10.1016/j.fertnstert.2005.01.137, 16084890.
15. Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, Chlebowski RT, Gelber R, Edge SB, Gralow J, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 2005, 23:619-629.
16. Attar E, Bulun SE. Aromatase inhibitors: the next generation of therapeutics for endometriosis?. Fertil Steril 2006, 85:1307-1318. 10.1016/j.fertnstert.2005.09.064, 16647373.
17. Vercellini P, Crosignani P, Somigliana E, Vigano P, Frattaruolo MP, Fedele L. 'Waiting for Godot': a commonsense approach to the medical treatment of endometriosis. Hum Reprod 2011, 26:3-13. 10.1093/humrep/deq302, 21071490.
18. Bulun SE, Imir G, Utsunomiya H, Thung S, Gurates B, Tamura M, Lin Z. Aromatase in endometriosis and uterine leiomyomata. J Steroid Biochem Mol Biol 2005, 95:57-62. 10.1016/j.jsbmb.2005.04.012, 16024248.
19. Bulun SE, Yang S, Fang Z, Gurates B, Tamura M, Sebastian S. Estrogen production and metabolism in endometriosis. Ann N Y Acad Sci 2002, 955:75-85. discussion 86-78, 396-406, 10.1111/j.1749-6632.2002.tb02767.x, 11949967.
20. Soysal S, Soysal ME, Ozer S, Gul N, Gezgin T. The effects of post-surgical administration of goserelin plus anastrozole compared to goserelin alone in patients with severe endometriosis: a prospective randomized trial. Hum Reprod 2004, 19:160-167. 10.1093/humrep/deh035, 14688176.
21. Mousa NA, Bedaiwy MA, Casper RF. Aromatase inhibitors in the treatment of severe endometriosis. Obstet Gynecol 2007, 109:1421-1423. 10.1097/01.AOG.0000265807.19397.6d, 17540816.
22. Bohrer J, Chen CC, Falcone T. Persistent bilateral ureteral obstruction secondary to endometriosis despite treatment with an aromatase inhibitor. Fertil Steril 2008, 90:e2007-2009. 2004.
23. Sasson IE, Taylor HS. Aromatase inhibitor for treatment of a recurrent abdominal wall endometrioma in a postmenopausal woman. Fertil Steril 2009, 92:e1171-1174. 1170.
24. Yohannes P. Ureteral endometriosis. J Urol 2003, 170:20-25. 10.1097/01.ju.0000054836.32660.9e, 12796637.
25. Ghezzi F, Cromi A, Bergamini V, Bolis P. Management of ureteral endometriosis: areas of controversy. Curr Opin Obstet Gynecol 2007, 19:319-324. 10.1097/GCO.0b013e328216f803, 17625412.
26. Duffy S, Jackson TL, Lansdown M, Philips K, Wells M, Pollard S, Clack G, Coibion M, Bianco AR. The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment. Hum Reprod 2006, 21:545-553.
27. Rabaglio M, Sun Z, Price KN, Castiglione-Gertsch M, Hawle H, Thurlimann B, Mouridsen H, Campone M, Forbes JF, Paridaens RJ, et al. Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. Ann Oncol 2009, 20:1489-1498. 10.1093/annonc/mdp033, 2731016, 19474112.
28. Hillner BE, Ingle JN, Chlebowski RT, Gralow J, Yee GC, Janjan NA, Cauley JA, Blumenstein BA, Albain KS, Lipton A, Brown S. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003, 21:4042-4057. 10.1200/JCO.2003.08.017, 12963702.